{"id":"course-a3-vin","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a multi-agent chemotherapy combination where doxorubicin and cyclophosphamide act as alkylating/intercalating agents to damage cancer cell DNA, while vincristine is a vinca alkaloid that disrupts microtubule formation and mitotic spindle function. The combination approach targets multiple mechanisms of cancer cell proliferation and is designed to improve efficacy in pediatric malignancies.","oneSentence":"Course A3 + Vin is a combination chemotherapy regimen combining doxorubicin, cyclophosphamide, and vincristine used to treat pediatric cancers.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:47.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pediatric cancers (specific indication not clearly defined in available data)"}]},"trialDetails":[{"nctId":"NCT04881838","phase":"PHASE3","title":"CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2021-03-01","conditions":"Pediatric Anaplastic Large Cell Lymphoma","enrollment":172}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Course A3 + Vin","genericName":"Course A3 + Vin","companyName":"Children's Cancer Group, China","companyId":"children-s-cancer-group-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Course A3 + Vin is a combination chemotherapy regimen combining doxorubicin, cyclophosphamide, and vincristine used to treat pediatric cancers. Used for Pediatric cancers (specific indication not clearly defined in available data).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}